CP-31398

CP-31398 is a **small molecule p53 modulator** in the styrylquinazoline chemical class, identified by Pfizer. It was developed to selectively restore wild-type transcriptional activity to mutant p53 protein—a key tumor suppressor—thereby reactivating its apoptotic and cell cycle arrest functions in cancer cells[6][1][3]. CP-31398 also stabilizes wild-type p53, increases p53 levels, and upregulates downstream targets such as p21, mdm2, PUMA, and Bax, leading to **apoptosis and cell cycle arrest**[2][1]. Additionally, CP-31398 may act through induction of reactive oxygen species (ROS), contributing to apoptosis even in p53-deficient or mutant cells, suggesting some p53-independent cytotoxic activity[5]. The drug has been studied in **skin cancer and multiple myeloma** models, with demonstrated antitumor effects in preclinical settings[3][5].

Brand names

CP-31398CP31398CP 31398

Other names

CP-31398CP31398CP 31398styrylquinazoline